Bristol Myers Squibb (BMY) reported that its growth portfolio—a collection of over a dozen newer drugs—generated nearly $7.7 billion in revenue in a single quarter, representing a 12% increase compared to the same quarter in 2025 [1]. This strong performance demonstrates the pharmaceutical giant's continued execution in new drug development, with the growth portfolio now accounting for nearly 60% of the company's total drug revenues as of the third quarter [1]. Despite this success, investors remain downbeat on the stock, creating an attractive dividend yield of 4.3%, which is notably above the S&P 500 index yield of roughly 1.1% and the average healthcare and drug stock yields of 1.3% [1].
The company's valuation metrics present a compelling case for value investors. Bristol Myers Squibb trades at a 13x price-to-earnings ratio, significantly below the pharma industry average of roughly 28x [1]. The dividend payout ratio of approximately 55% leaves ample room for financial flexibility, and the company has increased its dividend regularly over more than three decades without any cuts despite difficult periods, demonstrating strong board commitment to shareholder returns [1]. The stock closed at $58.80 with a market capitalization of $119.25 billion, trading within a 52-week range of $45.52 to $68.64 [1].
However, a significant headwind looms for the company. The legacy portfolio still accounts for approximately 40% of revenues, or roughly $5.4 billion, with one drug—Eliquis—responsible for nearly $4.7 billion of that total [1]. Eliquis is set to face generic competition as soon as 2028, which will likely cause revenues from this drug to decline sharply [1]. This patent cliff concern is cited as the primary reason investors remain cautious about Bristol Myers Squibb's stock despite the growth portfolio's strong performance [1]. The article suggests that while extremely conservative investors might wait until after Eliquis' patent expiration, patent expirations are a normal part of the pharmaceutical business, and the company's strong execution in new drug development may offset future revenue losses [1].
CONCLUSION
Bristol Myers Squibb demonstrates solid operational execution with its growth portfolio generating $7.7 billion in quarterly revenue and growing 12% year-over-year, while trading at an attractive 13x P/E ratio with a 4.3% dividend yield [1]. The primary market concern remains the 2028 patent expiration of Eliquis, which currently generates $4.7 billion in annual revenue and represents a significant portion of the company's legacy portfolio [1]. Investors must weigh the company's strong new drug development capabilities against the near-term revenue headwinds from patent cliffs.